<DOC>
	<DOCNO>NCT01092624</DOCNO>
	<brief_summary>This study evaluate effect pessary therapy , without Solifenacin ( Vesicare ) , symptom active bladder bladder function woman overactive bladder symptom pelvic organ prolapse . Study Hypotheses : Null hypothesis , HO : Reduction anterior vaginal wall prolapse treatment solifenacin improve overactive bladder symptom reduction anterior vaginal wall prolapse placebo . Alternate hypothesis , HA : Reduction anterior vaginal wall prolapse treatment solifenacin improve overactive bladder symptom reduction anterior vaginal wall prolapse placebo .</brief_summary>
	<brief_title>Clinical Trial Solifenacin Versus Placebo Plus Pessary Women With Vaginal Prolapse</brief_title>
	<detailed_description>Pelvic organ prolapse ( POP ) affect approximately half woman age 501 . The common type POP anterior vaginal wall prolapse . Symptoms associate POP include : voiding dysfunction , defecatory dysfunction vaginal bulge symptom . Treatments pelvic organ prolapse include among option , vaginal pessary surgery . Several study document improved vaginal bulge symptom woman treat pessary2,3,4 ; however , data sparse regard effect pessary low urinary tract symptom , specifically regard active bladder symptom . Overactive bladder , observe approximately 40 % woman 50 year age old , common woman pelvic organ prolapse . Two retrospective study show improvement woman overactive bladder symptom follow treatment vaginal pessary . One study ( use non-validated questionnaire ) find , two month follow-up , patient successfully fit pessary experienced reduction slightly less half urge incontinence symptoms.5 A second study ( use Sheffield pelvic organ prolapse symptom questionnaire ) , reveal 4 month insertion pessary , 38 % patient experience reduced urinary urgency , 29 % experience reduced urge urinary incontinence6 . Despite data , many woman stop use pessary secondary complaint increase urine incontinence . More information need pessary therapy impact bladder function . Specific Aim ( ) : This study prospectively evaluate woman pelvic organ prolapse overactive bladder symptom treat either 1. pessary solifenacin , 2. pessary placebo . We assess effect therapy overactive bladder symptom course 14-week study .</detailed_description>
	<mesh_term>Prolapse</mesh_term>
	<mesh_term>Pelvic Organ Prolapse</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<criteria>Female Age â‰¥ 18 year Have experience symptom overactive bladder ( e.g. , urinary urgency , frequency , urge incontinence ) least 3 month . Specifically woman must average 8 void 24 hour 3 episode urinary urgency urge incontinence 72 hour diary complete . A practitioner trained pelvic organ prolapse quantification examination evaluate woman 's pelvic organ support vaginal dimension . Women stage 1 great vaginal prolapse eligible study . The presence factor would contraindicate use antimuscarinic medication ( e.g . urine retention , narrow angle glaucoma , uncontrolled constipation , dementia ) An exist condition would contraindicate use vaginal pessary ( e.g. , patient 's vaginal length &lt; 6 cm ) Patient currently use vaginal pessary . Patient unable tolerate object vagina Patient history cervical , vaginal endometrial cancer Patient able speak English Patient currently use anticholinergic medication , use one past 30 day Patients mixed urine incontinence predominantly stress urine incontinence ( determined baseline PFDI ) Patients know allergy solifenacin . Patients severe hepatic impairment .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>void dysfunction</keyword>
	<keyword>defecatory dysfunction</keyword>
	<keyword>vaginal bulge symptom</keyword>
</DOC>